Novo Nordisk A/S Investigated by the Portnoy Law Firm

LOS ANGELES, March 17, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Novo Nordisk A/S (“Novo Nordisk" or the "Company") (NYSE:NVO) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via http://portnoylaw.com/novo-nordisk-a-s. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

On February 23, 2026, Novo Nordisk issued a press release “announc[ing] headline results from REDEFINE 4, an open-label phase 3 trial from the global REDEFINE clinical trial programme.” The press release reported that Novo Nordisk’s experimental drug CagriSema failed to achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly’s rival drug tirzepatide after 84 weeks.

On this news, Novo Nordisk’s American Depositary Receipt (“ADR”) price fell $7.79 per ADR, or 16.43%, to close at $39.63 per ADR on February 23, 2026.

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.

Admitted CA, NY and TX Bar

lesley@portnoylaw.com

310-692-8883

www.portnoylaw.com

Attorney Advertising